Immunotherapy: Magic Bullet to Change the Future Therapeutics
- 1st Edition, Volume 144 - March 26, 2025
- Imprint: Academic Press
- Editors: Vijay Kumar Prajapati, Rossen Donev
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 1 5 9 4 6 - 6
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 1 5 9 4 7 - 3
FORMTEXT Immunotherapy is emerging as a novel and reliable therapeutic technique for treating diseases such as autoimmunity, HIV/AIDS, allergy and cancers. Immunotherapy change or… Read more
Purchase options
FORMTEXT Immunotherapy is emerging as a novel and reliable therapeutic technique for treating diseases such as autoimmunity, HIV/AIDS, allergy and cancers. Immunotherapy change or modulate our immune system functionalization and activate it to kill pathogen infected cells or affected cells. Development in the field of Immunology, Molecular Biology, and Pharmaceutical Sciences empower the immune system for protecting us agaist number of pathogenic infections. This volume consisit of the chapters from the different stalwarts of the field coveriing the topic such as Immunotherapy past and present, Oncolytic virus based therapy, CAR-T cell therapy, antibody engineering, adjuvant engineering etc. Chapters covered in this volume discuss the immunological translational research in the field of human cancer, parasitic and infectiouds diseases. This volume incudes the chapter describing the tools developed by scientist to engineers safe and effective antibody which can be used as powerful medicine durig human disease conditions. This volume will reflect the secret of biological sciences and technology in the field on immunology to develop safe and efficacious immune molecules based magic bullet to provide absolute cure. This volume will be helpful to the early career researchers and students working in the field of basic and applied immunological sciences.
- Immunotherapy
- Monoclonal antibody
- Cytokines
Post-graduate students and early career researcher.
1. Historical timeline of immunotherapeutic developments
Vijay Kumar Prapajati
2. Development of Pancreatic cancer immunotherapy
Vijay Kumar Prapajati
3. Exploring immunotherapy with Antibody-drug conjugates in solid tumor oncology
Vijay Kumar Prapajati
4. Exploring development of check-point inhibitors to develop human immunotherapy
Vijay Kumar Prapajati
5. Immunotherapy in the Management of Inflammatory Bone Loss in Osteoporosis
Rupesh K. Srivastava
6. Immunotherapy to CD5, a T cell antigen having roles from development to peripheral function: future prospective and challenges
Ambak K. Rai
7. Nanobody based cancer immunotherapy: prospects and challenges
Sanjana Mehrotra
8. Monoclonal antibodies- a repertoire of therapeutics
Suman Tapryal
9. Navigating the Landscape: A Comprehensive Overview of Computational Approaches in Developing Therapeutic Antibodies
Aditya K. Padhi
10. Host Directed Immunotherapy in chronic diseases: From cancer to parasitic infections
Rajiv Kumar
Vijay Kumar Prapajati
2. Development of Pancreatic cancer immunotherapy
Vijay Kumar Prapajati
3. Exploring immunotherapy with Antibody-drug conjugates in solid tumor oncology
Vijay Kumar Prapajati
4. Exploring development of check-point inhibitors to develop human immunotherapy
Vijay Kumar Prapajati
5. Immunotherapy in the Management of Inflammatory Bone Loss in Osteoporosis
Rupesh K. Srivastava
6. Immunotherapy to CD5, a T cell antigen having roles from development to peripheral function: future prospective and challenges
Ambak K. Rai
7. Nanobody based cancer immunotherapy: prospects and challenges
Sanjana Mehrotra
8. Monoclonal antibodies- a repertoire of therapeutics
Suman Tapryal
9. Navigating the Landscape: A Comprehensive Overview of Computational Approaches in Developing Therapeutic Antibodies
Aditya K. Padhi
10. Host Directed Immunotherapy in chronic diseases: From cancer to parasitic infections
Rajiv Kumar
- Edition: 1
- Volume: 144
- Published: March 26, 2025
- Imprint: Academic Press
- Language: English
VP
Vijay Kumar Prajapati
Dr. Vijay Kumar Prajapati is working as an Associate Professor at Department of Biochemistry, University of Delhi South Campus, New Delhi, India. He has extensive experience in the field of Cell-death Research, Parasitology and therapeutic developments for infectious diseases. He has published more than 100 research articles in the international journal with >20 book chapters with reputed publishers. He is a recipient of prestigious INSA Medal for Young Scientist from Indian National Science Academy (INSA) and Associate from Indian Academy of Sciences, Benguluru. He has published research work in the prestigious journal such as Journal of Infectious Diseases, Clinical Infectious Diseases, Scientific Reports, Medicinal Research Review, Journal of Cellular Physiology etc. His current h-index is 43 with more than 6000 citations.
Affiliations and expertise
Department of Biochemistry, University of Delhi South Campus, IndiaRD
Rossen Donev
Rossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) and Cardiff University. In 2007 he was awarded a New Investigator Grant Award from the Medical Research Council (UK) to establish himself as an independent Principle Investigator. In 2010 Dr. Donev was appointed Senior Lecturer at Swansea University. In 2016 Dr. Donev joined MicroPharm Ltd (UK) where currently he is Head of Research. He has published more than 60 research papers, chaired scientific meetings and given invited plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other journals. His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on development of immunotherapeutics for non-systemic applications.
Affiliations and expertise
Head of Research, MicroPharm Limited, UKRead Immunotherapy: Magic Bullet to Change the Future Therapeutics on ScienceDirect